Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis

TAO Synergies Inc.

Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.
Trial expected to commence in Q4 2023 at Cleveland Clinic's Mellen Center for Multiple Sclerosis.
Synaptogenix had approximately $35.8M in cash as of March 31, 2023, sufficient to fund the trial and other developments.
Bryostatin-1 targets synaptic regeneration and anti-inflammatory pathways; cognitive impairment is a key unmet need in MS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.